Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : John Dessauer's Investors World -- Ignore unavailable to you. Want to Upgrade?

To: Diogeron who wrote (1990)	1/23/1999 5:38:00 AM
From: R Chen	Read Replies (1) \| Respond to of 2346

To all, ERICY also recieved negative press in IBD. article mentioned that of IBD's A+,A, and A- rated funds 41 sold ERICY and only 12 bought. Company warned 98 EPS would be 15-25% lower than expected. Company does not expect to meet 99 growth goals. IBD cites decerating profit growth for last three quarters of33%,11%, and last of only 5% .Author sees above imfo as possible signs of trouble. Good luck R Chen

To: Diogeron who wrote (1990)	1/23/1999 10:19:00 AM
From: robert emann	Read Replies (1) \| Respond to of 2346

Dear Diogeron; I have not seen the WSJ article yet but will try to see it at my nearby library. I bought some about 12-18 months ago in the mid $50 range with the intent of holding for a long time. Ever since then I noticed every analyst criticizes Novartis for slow single digit top line sales growth yet earnings continue to improve nicely and the market price is up about 80% plus there was a distribution not to long ago for the chemical business. Not a bad return. Not a trading stock , but good buy and hold type. Regards Bob